Current Drug Delivery 2009-04-01

Design and in vitro evaluation of a novel vaginal drug delivery system based on gelucire.

M Patel Geeta, M Patel Madhabhai

Index: Curr. Drug Deliv. 6(2) , 159-65, (2009)

Full Text: HTML

Abstract

Carbamazepine indicated for the control of epilepsy, undergoes extensive hepatic first-pass metabolism after oral administration. A vaginal dosage form of carbamazepine is not commercially available. Conventional suppository having poor retention in the vaginal tract, as they are removed in a short time by the tract's self-cleansing action, having poor patient compliance. To overcome such problems, delivery system with mucoadhesive polymers polyox WSR N-60K and Ucarflock 302 that prolong drug permanence on the vaginal mucosa were developed. In the present study the suitability of gelucires to formulate vaginal pesseries was investigated. The possible modification of carbamazepine release kinetics by using gelucires blends and hydrophilic additives in the pesseries was evaluated. It was observed that among gelucire grades melting point higher than 37 degrees C, the release rate proved to be highly dependant on HLB value and matrix composition. In most of the formulations carbamazepine release occurred by disintegration and erosion of the matrices which is depending upon the vehicle employed. The aging study revealed that the formulations containing G50/13 and G50/13-G44/14 blends undergo some changes during one year of shelf aging. From the results obtained it can be concluded that different gelucire grades and their blends along with hydrophilic polymer could be successesively used to formulate prolong release carbamazepine pesseries.


Related Compounds

Related Articles:

A Comparison of the α2/3/5 Selective Positive Allosteric Modulators L-838,417 and TPA023 in Preclinical Models of Inflammatory and Neuropathic Pain.

2011-01-01

[Adv. Pharmacol. Sci. 2011 , 608912, (2011)]

PDADMAC flocculation of Chinese hamster ovary cells: enabling a centrifuge-less harvest process for monoclonal antibodies.

2015-01-01

[MAbs 7(2) , 413-28, (2015)]

Localized experimental bone metastasis drives osteolysis and sensory hypersensitivity at distant non-tumor-bearing sites.

2015-08-01

[Breast Cancer Res. Treat. 153 , 9-20, (2015)]

CD133 is a marker of bioenergetic stress in human glioma.

2008-01-01

[PLoS ONE 3 , e3655, (2008)]

Crosstalk from non-cancerous mitochondria can inhibit tumor properties of metastatic cells by suppressing oncogenic pathways.

2013-01-01

[PLoS ONE 8 , e61747, (2013)]

More Articles...